Corey McCann - Jan 14, 2023 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
President and CEO, Director
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Stock symbol
PEARQ
Transactions as of
Jan 14, 2023
Transactions value $
$0
Form type
4
Date filed
1/18/2023, 04:03 PM
Previous filing
Feb 18, 2022
Next filing
Jan 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PEARQ Common Stock Options Exercise $0 +88K +1.08% $0.00 8.25M Jan 14, 2023 Direct
holding PEARQ Class A Common Stock 1.69M Jan 14, 2023 by The Corey M. McCann Irrevocable Trust of 2021 F1, F2
holding PEARQ Class A Common Stock 987K Jan 14, 2023 by The McCann Family Trust F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Restricted Stock Units Options Exercise $0 -88K -33% $0.00 179K Jan 14, 2023 Common Stock 88K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, with respect to these shares, except to the extent of his pecuniary interest therein.
F2 Shares held in The Corey M. McCann Irrevocable Trust of 2021. The trustee of The Corey M. McCann Irrevocable Trust of 2021 is Mia E. Moll.
F3 Shares held in The McCann Family Trust. The trustee of The McCann Family Trust is Concord Trust Company.
F4 Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F5 The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025.